SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) OF REXALL TABLETS 500MG

1. NAME OF THE MEDICINAL PRODUCT

REXALL 500 mg Tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 500 mg of Paracetamol.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Tablet.

White round flat shaped tablet with flat edges

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Paracetamol is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhea.

4.2 Posology and method of administration

Posology

Adults, Elderly and Children over 16 years:

Two tablets every four hours as required. Not more than eight tablets in 24 hours Do not take for more than 3 days without consulting your doctor.

These doses should not be given more frequently than every four hours nor should more than four doses be given in any 24 hour period.

Paediatric population

Not recommended for children under 10 years of age.

Children aged 10 to 15 years:

One Tablet every four to six hours when necessary to a maximum of four doses in 24 hours. Do not take for more than 3 days without consulting your doctor.

These doses should not be repeated more frequently than every four to six hours nor should more than four doses be given in any 24 hour period.

Method of administration

For oral administration

4.3 **Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

4.4 Special warnings and precautions for use

Paediatric population

Not recommended for children under the age of 10 years.

Care is advised in the administration of paracetamol to patients with severe renal or severe hepatic impairment. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.

Do not exceed the recommended dose.

Do not take for more than 3 days without consulting a doctor.

Do not take with any other paracetamol-containing products.

If symptoms persist consult your doctor.

Keep out of the reach of children.

Immediate medical advice should be sought in the event of an overdose, even if you feel well, because of the risk of delayed, serious liver damage.

4.5 **Interaction with other medicinal products and other forms of interaction**

The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by cholestyramine.

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.

4.6 **Fertility, pregnancy and lactation**

Pregnancy

Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use. A large amount of data on pregnant women indicate neither malformative, nor feto/neonatal toxicity. Paracetamol can be used during pregnancy if clinically needed however it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency.

Breastfeeding

Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breast feeding.

4.7 **Effects on ability to drive and use machines**

Paracetamol has no influence on the ability to drive and use machines.

4.8 **Undesirable effects**

The information below lists reported adverse reactions, ranked using the following frequency classification:

Very common (Ó1/10); common (Ó1/100 to <1/10); uncommon (Ó1/1,000 to <1/100); rare (Ó1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Immune system disorders

Hypersensitivity including skin rash may occur.

Not known: anaphylactic shock; angioedema

Blood and lymphatic system disorders

Not known: blood dyscrasias including thrombocytopenia and agranulocytosis

Skin and subcutaneous disorders

Very rare cases of serious skin reactions have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 **Overdose**

Liver damage is possible in adults who have taken 10g or more of paracetamol. Ingestion of 5g or more of paracetamol may lead to liver damage if the patient has risk factors (see below).

Risk factors

If the patient:

Åis on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St. John's Wort or other drugs that induce liver enzymes, or

Åregularly consumes ethanol in excess of recommended amounts, or

Åis likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms

Symptoms of paracetamol overdosage, in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, gastrointestinal bleeding and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria may develop even in the absence of severe liver damage.

Cardiac arrhythmias and pancreatitis have been reported.

Management

Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines (see BNF overdose section).

Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with the NPIS or a liver unit.

Further measures will depend on the severity, nature and course of clinical symptoms of paracetamol intoxication and should follow standard intensive care protocols.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

ATC code: N02B E01, Other analgesics and antipyretics

Paracetamol is an effective analgesic and antipyretic agent, but has only weak anti-inflammatory properties. Its mechanism of action is not fully understood. It has been suggested that it may act predominantly by inhibiting prostaglandin synthesis in the CNS and to a lesser extent through a peripheral action by blocking pain-impulse generation. The peripheral action may also be due to inhibition of prostaglandin synthesis or to inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation. Paracetamol probably produces an antipyretic action by a central effect on the hypothalamic heat-regulating center to produce peripheral vasodilation resulting in increased blood flow through the skin, sweating and heat loss. The central action probably involves inhibition of prostaglandin synthesis in the hypothalamus. The drug has no effect on the cardiovascular and respiratory systems, and unlike salicylates it does not cause gastric irritation or bleeding.

5.2 **Pharmacokinetic properties**

Paracetamol is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring about 30 minutes to 2 hours after ingestion. It is metabolised in the liver (90-95%) and excreted in the urine mainly as the glucuronide and sulphate conjugates. Less than 5% is excreted as unchanged paracetamol. The elimination half-life varies from about 1 to 4 hours. Plasma protein binding is negligible at usual therapeutic concentrations but increases with increasing concentrations.

A minor hydroxylated metabolite (N-acetyl-p-benzoquinoneimine) which is usually produced in very small amounts by mixed-function oxidases in the liver and which is usually detoxified by conjugation with liver glutathione may accumulate following paracetamol overdosage and cause liver damage. The time to peak plasma concentration of paracetamol is 0.5 to 2 hours, the time to peak effect 1 to 3 hours and the duration of action 3 to 4 hours.

5.3 **Preclinical safety data**

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

Maize starch

Sodium Starch Glycolate

Povidone

Magnesium Stearate.

6.2 **Incompatibilities**

Not applicable

6.3 **Shelf life**

36 months.

6.4 **Special precautions for storage**

Store in the original package

6.5 **Nature and contents of container**

Polypropylene containers

Pack sizes: 1000

Polyethylene bag contained in cardboard cartons

Pack sizes: 86 and 1000

Blister strips: 35gsm Glassine (pergamin) paper/9 micron soft temper Aluminium foil/250 micron PVC contained in cardboard cartons.

Pack sizes: 96

HDPE Duma containers

Pack size: 4

Not all pack sizes are marketed.

6.6 **Special precautions for disposal and other handling**

Not applicable

7. **MARKETING AUTHORISATION HOLDER**

Daily-Need Industries Limited
Plots 9/10 Unity close, Oshodi Scheme Industrial Estate, Lagos
www.dailyneedgroup.com,
info@dailyneedgroup.com

8. **MARKETING AUTHORISATION NUMBER(S)**

B4-3725

9. **DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION**

August 2015/August 2020

10. **DATE OF REVISION OF THE TEXT**

August 2020

Company Contact Details

Daily-Need Industries Limited
Plots 9/10 Unity close, Oshodi Scheme Industrial Estate, Lagos
www.dailyneedgroup.com,
info@dailyneedgroup.com